Moderna Reports Significant Drop in Covid Vaccine Sales for 2023, Forecasts Future Growth with Combination Shots

Moderna, a key player in the global fight against the COVID-19 pandemic, announced on January 8, 2024, that its COVID vaccine sales experienced a sharp decline of approximately two-thirds in 2023, amounting to $6.7 billion. This plunge in revenue, while significant, aligns with the company's forecast for the year, despite the stark contrast from the over $18 billion recorded in 2022.

The decline in demand for Moderna's COVID vaccine reflects the changing landscape as cases diminished and public concern waned from the peak of the pandemic. With the vaccine being the company's sole commercially available product, Moderna faced a nearly 45% decrease in its shares throughout the past year due to weakened demand.

Become a Subscriber

Please purchase a subscription to continue reading this article.

Subscribe Now

Of the $6.7 billion in revenue, approximately $6.1 billion stemmed directly from sales of the COVID vaccine, while an additional $600 million represented deferred revenue associated with Moderna's collaboration with Gavi, a global vaccine organization facilitating a worldwide shot distribution program.

Despite the decrease in COVID vaccine sales, the company reported an increase in its market share within the U.S., capturing 48% in 2023 compared to 37% in 2022. However, the company anticipates a further decline in sales from the vaccine in 2024, with a reiterated full-year sales guidance of approximately $4 billion.

Looking ahead, Moderna envisions a return to sales growth in 2025, banking on the launch of new products. The company currently has 45 products in development, with nine in late-stage trials. Notable among these is a combination shot targeting both COVID and the flu, which could secure approval as early as 2025.

Recently, the company's CFO, Jamey Mock, highlighted the potential impact of combination vaccines on convenience and cost reduction, emphasizing their positive influence on overall vaccination rates. The company's forward-looking strategy includes anticipating FDA approval for its vaccine against respiratory syncytial virus (RSV) in April 2024.

While acknowledging the current challenges, Moderna remains optimistic about its future prospects, with expectations to achieve a "break-even" point by 2026. The company's commitment to innovation and a diversified product portfolio, including the development of combination vaccines, positions it strategically in the evolving landscape of infectious disease prevention.

Moderna's 2023 financial results reflect the shifting dynamics of the COVID vaccine market, prompting the company to explore new avenues and combination shots for sustained growth in the coming years.